Phospholipase A2 (PLA2) hydrolyses the fatty acyl ester bond at the sn-2 position of glycerophospholipids and produces free fatty acids and lysophospholipids. Cellular calcium dependent PLA2s have been thought to participate in both the regulation of phospholipid metabolism in biomembranes and eicosanoid biosynthesis.1 It has been shown that cellular calcium dependent PLA2s of mammalian origin can be classified into at least three groups according to their distinct characteristics in primary structure2-6: the pancreatic type (group I), the viperid and crotalid type (group II), and the cytosolic high molecular weight type. Group I PLA2 is considered to be one of the digestive enzymes, and it is abundant in pancreatic juice. Human group II PLA2 was purified from spleen,7 platelets, and synovial fluid. 5 Recently, we purified group II PLA2 from human ileal mucosa and provided evidence for the presence of immunoreactivity and messenger RNA (mRNA) of group II PLA2 in human ileal and colonic mucosa.8 9 Recent studies suggest that calcium dependent PLA2s, group II enzyme in particular, participate in inflammatory response either through a direct action or through an indirect action by metabolites of phospholipids.10-3 It has been reported that immunoreactive group II PLA2 (IR-PLA2 II) values and PLA2 enzymatic activity were increased in serum samples and synovial fluid of patients with rheumatoid arthritis, 14-16 and 21 Crohn's disease patients had received resection of sigmoid colon. In patients with Crohn's disease, the colonic mucosa was evaluated with regard to erythema, erosions or ulcers on colonoscopic examination. The presence of any of these signs was considered to show active inflammation. All Crohn's disease patients were receiving special diets including elementary and low residual diet. Colonic mucosal biopsy for assay of PLA2 activity and IR-PLA2
II content was performed in 13 Crohn's disease patients during endoscopically diagnosed active phase, of whom seven were receiving treatment with sulphasalazine (0 5-3 0 g/day), and six were receiving no drugs. A similar biopsy was performed in 14 Crohn's disease patients during endoscopically diagnosed inactive phase, of whom eight were receiving treatment with sulphasalazine (0 5-3 0 g/day), and six were receiving no drugs. In active and inactive Crohn's disease patients biopsy samples were obtained from macroscopically involved mucosa.
In 21 patients with ulcerative colitis (11 men and 10 women) aged 20-58 years (mean (SD) age of 34-3 (2 6)), colonoscopy was performed on a total of 26 occasions. None of the patients had prior surgical treatment. In patients with ulcerative colitis, all colonoscopic findings were graded from 1 to 4 according to the severity of inflammation using the criteria of Matts.26 When the score was 1 or 2, the inflammation was considered to be mild, and when the score was 3 or 4, the inflammation was considered to be severe. Colonic mucosal biopsy samples for assay of PIA2 activity and IR-PIA2 II content were obtained from endoscopically diagnosed mildly inflamed mucosa in 13 ulcerative colitis patients, of whom four were receiving no drugs, three were receiving treatment with sulphasalazine (1 5-3-0 g/day), and six were receiving treatment with predonisolone (5-20 mg/day) in addition to sulphasalazine (1 5-4 0 g/day). Similar samples were obtained from severely inflamed mucosa in 13 ulcerative colitis patients, of whom four were receiving no drugs, seven were receiving treatment with sulphasalazine (1 5-4-0 g/day), and two were receiving treatment with predonisolone (5-30 mg/day) in addition to sulphasalazine (1 5-4 The biopsy samples were homogenised in 30 volumes of 10 mM TRIS-HCI (pH 7.4), and PLA2 activity was determined as reported27 28 using 0-8 mM 1-palmitoyl-2-oleoyl-snglycero-3-phospho-glycerol (POPG) as a substrate in the presence of 5 mM cholate. Fatty acids released by PLA2 action were labelled with 9-anthryl-diazomethane, and the derivatised fatty acids were separated by reverse phase high performance liquid chromatography, and oleic acid was quantitated using marganic acid as an internal standard. Calcium dependent PLA2 activity was estimated as the difference between the activity assayed in the presence of 5 mM CaC12 and that in the presence of 10 mM EDTA.
The protein concentrations of the homogenates of colonic biopsy samples were determined with bicinchoninic acid protein assay reagent (Pierce). severely inflamed colonic mucosas of ulcerative colitis patients. Although mucosal IR-PLA2 II content of inactive Crohn's disease patients tended to be increased, it did not significantly differ from that of the controls. The same tendency was seen in IR-PLA2 II content in mildly inflamed mucosa of ulcerative colitis patients.
Colonic mucosal PLA2 activities of the controls, and all patients with Crohn's disease and ulcerative colitis were 9 1 (1.0), 30 25 -5 (6-1) and 30 9 (5-1) nmol/min/mg protein, respectively. Mucosal PIA2 activity of active Crohn's disease patients was significantly higher than that of inactive Crohn's disease patients (p<001) and controls (p<001). The activity in severe ulcerative colitis patients was significantly higher than that in the controls (p<001). There was no significant difference in PLA2 activity, however, between mildly inflamed and severely inflamed colonic mucosas of ulcerative colitis patients. Although mucosal PLA2 activities of inactive Crohn's disease or mild ulcerative colitis patients tended to be increased, there was no significant difference between those of the patients and controls.
On regression analysis, PLA2 activity was closely correlated with IR-PIA2 II content in the colonic biopsy samples obtained from the patients with Crohn's disease (r=0-96, p<0 01) or ulcerative colitis (r= 092, p<0 01) (Fig 3) .
There was no significant difference in colonic mucosal PLA2 activity and IR-PLA2 II content between the Crohn's disease patients not receiving drugs and those receiving treatment with sulphasalazine. There was also no significant difference found in colonic mucosal PLA2 activity and IR-PLA2 II content between the ulcerative colitis patients not treated with drugs and those receiving sulphasalazine, between the patients treated with no drugs and those receiving predonisolone in addition to sulphasalazine, and between the patients treated with sulphasalazine and predonisolone in addition to sulphasalazine. Although significant difference was found in age between Crohn's disease patients and controls, no correlation was found between patients' age and either colonic mucosal IR-PLA2 II content or PLA2 activity in the controls. Almer et al 30 reported that no significant difference was found in colonic mucosal PLA2 activity between ulcerative colitis patients and control patients without inflammatory bowel disease in contrast with the results of this study. In their study, colonic mucosal PLA2 activity was estimated at an acidic pH value of 6-0 and in the presence of 2 mM CaCl2. Under these conditions alkaline active calcium dependent and calcium independent PLA2s, and lysosomal PLA2s with acidic pH optimum may contribute to the measurable activity. On the other hand, we selected a pH of 8X5 for assaying PLA2 activity where group II PLA2 is optimally active and used POPG/cholate mixed micelles, the best substrate for group II PLA2.9 28 Calcium dependent PLA2 activity was estimated by subtracting the value of activity in the presence of EDTA from that in the presence of Ca2+ ion. Therefore, the discrepancy on mucosal PLA2 activity in ulcerative colitis patients could be explained by the difference in assay conditions used.
In previous studies,8 25 we reported that serum PLA2 activity and IR-PIA2 II concentrations were increased in active Crohn's disease patients and reflected the colonoscopic severity of inflammation in ulcerative colitis patients. The origin of serum PLA2 in these patients is still unknown. The results of this study suggest that an increased concentration of group II PLA2 in serum samples of patients with Crohn's disease and ulcerative colitis may be in part explained by leakage of group II PLA2 from the inflamed mucosa.
The mechanism for an increase in group II PLA2 in the inflamed colonic mucosa of patients with Crohn's disease and ulcerative colitis is unknown. Recently, it has been reported that various cytokines, such as interleukins 1 and 6, and tumour necrosis factor alpha caused an increase in group II PLA2 mRNA and PIA2 activity.'2 13 33 High concentrations of interleukin 1 and interleukin 6 in mucosal biopsy specimens and an increased production of tumour necrosis factor alpha by mononuclear cells isolated from intestinal biopsy specimens have been reported in patients with active inflammatory bowel disease.34-36 These findings raise a possibility that these cytokines stimulate intestinal mucosal group II PLA2 synthesis and secretion, which may play a part in intestinal inflammatory process in inflammatory bowel disease. There is no direct evidence, however, that these cytokines elicit the expression of group II PLA2 in vivo. The role and regulation of group II PLA2 in intestinal inflammation of inflammatory bowel disease remain to be clarified.
